SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (OTCBB:LJPC), a biopharmaceutical company dedicated to improving and preserving human life by acquiring and developing innovative pharmaceutical products, reported today that its Board of Directors approved a 1-for-100 reverse stock split, which will be effected after the close of market on April 14, 2011.
